Clinical targeting of HIV capsid protein with a long-acting small molecule.

Adolescent Adult Anti-HIV Agents / chemistry Capsid Proteins / antagonists & inhibitors Cell Line Cells, Cultured Drug Resistance, Viral / genetics Female HIV-1 / drug effects Humans Male Middle Aged Models, Molecular Virus Replication / drug effects Young Adult

Journal

Nature

ISSN: 1476-4687

Titre abrégé: Nature

Pays: England

ID NLM: 0410462

Informations de publication

Date de publication:
08 2020

Historique:

received: 26 11 2019

accepted: 14 04 2020

pubmed: 3 7 2020

medline: 13 11 2020

entrez: 3 7 2020

Statut: ppublish

Résumé

Oral antiretroviral agents provide life-saving treatments for millions of people living with HIV, and can prevent new infections via pre-exposure prophylaxis

Identifiants

DOI: 10.1038/s41586-020-2443-1 PMID: 32612233 PMC: PMC8188729

pubmed: 32612233

doi: 10.1038/s41586-020-2443-1

pii: 10.1038/s41586-020-2443-1

pmc: PMC8188729

mid: NIHMS1709582

doi:

Substances chimiques

Anti-HIV Agents 0

Capsid Proteins 0

Types de publication

Clinical Trial Journal Article

Langues

eng

Sous-ensembles de citation

Pagination

614-618

Subventions

Organisme : NIAID NIH HHS

ID : P50 AI150464

Pays : United States

Références

Grant, R. M. et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N. Engl. J. Med. 363, 2587–2599 (2010).

pubmed: 21091279 pmcid: 3079639 doi: 10.1056/NEJMoa1011205

Baeten, J. M. et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N. Engl. J. Med. 367, 399–410 (2012).

pubmed: 22784037 pmcid: 3770474 doi: 10.1056/NEJMoa1108524

Molina, J. M. et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N. Engl. J. Med. 373, 2237–2246 (2015).

pubmed: 26624850 doi: 10.1056/NEJMoa1506273

Thigpen, M. C. et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N. Engl. J. Med. 367, 423–434 (2012).

pubmed: 22784038 doi: 10.1056/NEJMoa1110711

WHO. HIV/AIDS Fact Sheets, 15 November 2019. https://www.who.int/news-room/fact-sheets/detail/hiv-aids (WHO, 2019).

Emu, B. et al. Phase 3 study of ibalizumab for multidrug-resistant HIV-1. N. Engl. J. Med. 379, 645–654 (2018).

pubmed: 30110589 doi: 10.1056/NEJMoa1711460

Bangsberg, D. R. et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 15, 1181–1183 (2001).

pubmed: 11416722 doi: 10.1097/00002030-200106150-00015

Marrazzo, J. M. et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N. Engl. J. Med. 372, 509–518 (2015).

pubmed: 25651245 pmcid: 4341965 doi: 10.1056/NEJMoa1402269

Anderson, P. L. et al. Emtricitabine–tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci. Transl. Med. 4, 151ra125 (2012).

pubmed: 22972843 pmcid: 3721979 doi: 10.1126/scitranslmed.3004006

Gulick, R. M. & Flexner, C. Long-acting HIV drugs for treatment and prevention. Annu. Rev. Med. 70, 137–150 (2019).

pubmed: 30355266 doi: 10.1146/annurev-med-041217-013717

Thenin-Houssier, S. & Valente, S. T. HIV-1 capsid inhibitors as antiretroviral agents. Curr. HIV Res. 14, 270–282 (2016).

pubmed: 26957201 pmcid: 4785820 doi: 10.2174/1570162X14999160224103555

Carnes, S. K., Sheehan, J. H. & Aiken, C. Inhibitors of the HIV-1 capsid, a target of opportunity. Curr. Opin. HIV AIDS 13, 359–365 (2018).

pubmed: 29782334 pmcid: 6075716 doi: 10.1097/COH.0000000000000472

Scott, D. E., Bayly, A. R., Abell, C. & Skidmore, J. Small molecules, big targets: drug discovery faces the protein–protein interaction challenge. Nat. Rev. Drug Discov. 15, 533–550 (2016).

pubmed: 27050677 doi: 10.1038/nrd.2016.29

Freed, E. O. HIV-1 assembly, release and maturation. Nat. Rev. Microbiol. 13, 484–496 (2015).

pubmed: 26119571 pmcid: 6936268 doi: 10.1038/nrmicro3490

Ganser, B. K., Li, S., Klishko, V. Y., Finch, J. T. & Sundquist, W. I. Assembly and analysis of conical models for the HIV-1 core. Science 283, 80–83 (1999).

pubmed: 9872746 doi: 10.1126/science.283.5398.80

Yamashita, M. & Engelman, A. N. Capsid-dependent host factors in HIV-1 infection. Trends Microbiol. 25, 741–755 (2017).

pubmed: 28528781 pmcid: 5562514 doi: 10.1016/j.tim.2017.04.004

Huang, P. T. et al. FEZ1 is recruited to a conserved cofactor site on capsid to promote HIV-1 trafficking. Cell Rep. 28, 2373–2385 (2019).

pubmed: 31422020 pmcid: 6736649 doi: 10.1016/j.celrep.2019.07.079

Fernandez, J. et al. Transportin-1 binds to the HIV-1 capsid via a nuclear localization signal and triggers uncoating. Nat. Microbiol. 4, 1840–1850 (2019).

pubmed: 31611641 doi: 10.1038/s41564-019-0575-6

Carlson, L. A. et al. Three-dimensional analysis of budding sites and released virus suggests a revised model for HIV-1 morphogenesis. Cell Host Microbe 4, 592–599 (2008).

pubmed: 19064259 pmcid: 3454483 doi: 10.1016/j.chom.2008.10.013

Briggs, J. A., Wilk, T., Welker, R., Kräusslich, H. G. & Fuller, S. D. Structural organization of authentic, mature HIV-1 virions and cores. EMBO J. 22, 1707–1715 (2003).

pubmed: 12660176 pmcid: 152888 doi: 10.1093/emboj/cdg143

Yant, S. R. et al. A highly potent long-acting small-molecule HIV-1 capsid inhibitor with efficacy in a humanized mouse model. Nat. Med. 25, 1377–1384 (2019).

pubmed: 31501601 pmcid: 7396128 doi: 10.1038/s41591-019-0560-x

Graupe, M. et al. Therapeutic compounds. US patent 10,071,985 B2 (2018).

Matreyek, K. A., Yücel, S. S., Li, X. & Engelman, A. Nucleoporin NUP153 phenylalanine-glycine motifs engage a common binding pocket within the HIV-1 capsid protein to mediate lentiviral infectivity. PLoS Pathog. 9, e1003693 (2013).

pubmed: 24130490 pmcid: 3795039 doi: 10.1371/journal.ppat.1003693

Price, A. J. et al. CPSF6 defines a conserved capsid interface that modulates HIV-1 replication. PLoS Pathog. 8, e1002896 (2012).

pubmed: 22956906 pmcid: 3431306 doi: 10.1371/journal.ppat.1002896

Price, A. J. et al. Host cofactors and pharmacologic ligands share an essential interface in HIV-1 capsid that is lost upon disassembly. PLoS Pathog. 10, e1004459 (2014).

pubmed: 25356722 pmcid: 4214760 doi: 10.1371/journal.ppat.1004459

Bhattacharya, A. et al. Structural basis of HIV-1 capsid recognition by PF74 and CPSF6. Proc. Natl Acad. Sci. USA 111, 18625–18630 (2014).

pubmed: 25518861 doi: 10.1073/pnas.1419945112

Lee, K. et al. Flexible use of nuclear import pathways by HIV-1. Cell Host Microbe 7, 221–233 (2010).

pubmed: 20227665 pmcid: 2841689 doi: 10.1016/j.chom.2010.02.007

Perrier, M. et al. Prevalence of gag mutations associated with in vitro resistance to capsid inhibitor GS-CA1 in HIV-1 antiretroviral-naive patients. J. Antimicrob. Chemother. 72, 2954–2955 (2017).

pubmed: 29091184 doi: 10.1093/jac/dkx208

Li, G. et al. Functional conservation of HIV-1 Gag: implications for rational drug design. Retrovirology 10, 126 (2013).

pubmed: 24176092 pmcid: 4228425 doi: 10.1186/1742-4690-10-126

Yant, S. R. et al. In vitro resistance profile of GS-6207, a first-in-class picomolar HIV capsid inhibitor in clinical development as a novel long-acting antiretroviral agent. In 10th IAS Conference on HIV Science http://programme.ias2019.org/Abstract/Abstract/683 (IAS, 2019).

Tsiang, M. et al. Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile. Antimicrob. Agents Chemother. 60, 7086–7097 (2016).

pubmed: 27645238 pmcid: 5118987 doi: 10.1128/AAC.01474-16

Margot, N. A., Gibbs, C. S. & Miller, M. D. Phenotypic susceptibility to bevirimat in isolates from HIV-1-infected patients without prior exposure to bevirimat. Antimicrob. Agents Chemother. 54, 2345–2353 (2010).

pubmed: 20308382 pmcid: 2876391 doi: 10.1128/AAC.01784-09

Nakabayashi, H., Taketa, K., Miyano, K., Yamane, T. & Sato, J. Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res. 42, 3858–3863 (1982).

pubmed: 6286115

Balakrishnan, M. et al. Non-catalytic site HIV-1 integrase inhibitors disrupt core maturation and induce a reverse transcription block in target cells. PLoS ONE 8, e74163 (2013).

pubmed: 24040198 pmcid: 3767657 doi: 10.1371/journal.pone.0074163

Prichard, M. N. & Shipman, C. Jr. Analysis of combinations of antiviral drugs and design of effective multidrug therapies. Antivir. Ther. 1, 9–20 (1996).

pubmed: 11322261

Bam, R. A. et al. TLR7 agonist GS-9620 is a potent inhibitor of acute HIV-1 infection in human peripheral blood mononuclear cells. Antimicrob. Agents Chemother. 61, e01369-16 (2016).

pubmed: 27799218 pmcid: 5192112

Warren, T. K. et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 531, 381–385 (2016).

pubmed: 26934220 pmcid: 5551389 doi: 10.1038/nature17180

Hung, M. et al. Large-scale functional purification of recombinant HIV-1 capsid. PLoS ONE 8, e58035 (2013).

pubmed: 23472130 pmcid: 3589475 doi: 10.1371/journal.pone.0058035

Pornillos, O. et al. X-ray structures of the hexameric building block of the HIV capsid. Cell 137, 1282–1292 (2009).

pubmed: 19523676 pmcid: 2840706 doi: 10.1016/j.cell.2009.04.063

Pornillos, O., Ganser-Pornillos, B. K. & Yeager, M. Atomic-level modelling of the HIV capsid. Nature 469, 424–427 (2011).

pubmed: 21248851 pmcid: 3075868 doi: 10.1038/nature09640

Kissinger, C. R., Gehlhaar, D. K. & Fogel, D. B. Rapid automated molecular replacement by evolutionary search. Acta Crystallogr. D 55, 484–491 (1999).

pubmed: 10089360 doi: 10.1107/S0907444998012517

Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D 66, 213–221 (2010).

pubmed: 20124702 pmcid: 2815670

Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D 66, 486–501 (2010).

pubmed: 20383002 pmcid: 2852313